子宫腺肌病诊断中组织取样技术的系统评价
该系统评价通过检索MEDLINE和Cochrane图书馆,纳入14项研究共1909例患者,评估子宫腺肌病组织取样技术的诊断准确性。由于取样技术、取样部位和活检数量差异显著,灵敏度范围为22.2%至97.8%,特异度为78.5%至100%,无法给出最佳取样技术的确定性推荐。
要点
- 子宫腺肌病组织取样技术异质性显著,灵敏度随技术和活检数量变化大。
- 特异度较均一,各方法范围为78.5%至100%。
- 无法给出最佳取样技术的确定性推荐,取样应限于特定临床情境。
核心结论
- 由于组织取样技术异质性、患者人群多样及推荐意见存在明显冲突,无法就最佳组织取样技术给出确定性推荐。
- 对于基于症状和盆腔超声怀疑子宫腺肌病、已计划因不孕或盆腔痛行诊断性腹腔镜、且确诊结果可能有助于讨论术后症状复发预后并指导未来治疗的患者,限制子宫组织取样以确诊子宫腺肌病是合理的。
研究设计与样本
- 系统评价,遵循PRISMA指南,检索MEDLINE和Cochrane图书馆,使用MeSH主题词和关键词包括「Adenomyosis/diagnosis」「Adenomyosis/pathology」「Myometrium/pathology」及「Biopsy」「Hysteroscopy」「Laparoscopy」。
- 纳入14项研究,共1909例患者,来自12个不同国家、涉及6个不同大洲。
- 排除与子宫恶性肿瘤诊断相关的研究,以及通过切除性手术获取组织取样的研究。
主要发现
- 组织取样技术按活检途径分为宫内和宫外,并按是否经确认性子宫切除病理验证分类。
- 灵敏度因技术、取样部位和活检数量而异,最低为超声引导下经阴道活检可疑子宫病变(每例患者4次活检)的22.2%,最高为腹腔镜引导下子宫肌层活检可疑子宫病变(每例患者10次活检)的97.8%。
- 所有方法的特异度范围为78.5%至100%。
- 在经确认性子宫切除病理验证的所有组织取样技术中,阳性预测值范围为75.9%至100%,阴性预测值范围为46.4%至80%。
局限性
- 组织取样技术存在显著异质性。
- 患者人群多样。
- 推荐意见存在明显冲突。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate the accuracy of tissue sampling techniques for the diagnosis of adenomyosis. DATA SOURCES: Systematic Review via MEDLINE and the Cochrane Library searches. METHODS OF STUDY SELECTION: Review performed utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, utilizing MeSH terms and keywords including "Adenomyosis/diagnosis" or "Adenomyosis/pathology" or "Myometrium/pathology" and "Biopsy" or "Hysteroscopy" or "Laparoscopy." Articles initially screened by title and abstract to include relevant studies with reference lists cross-referenced to find additional studies. Articles related to the diagnosis of uterine malignancy or studies in which tissue sampling was obtained through excisional surgical procedures were excluded from the review. TABULATION, INTEGRATION, AND RESULTS: Fourteen studies were identified describing tissue sampling techniques to diagnose adenomyosis, with a total of 1909 patients, from 12 different countries, involving 6 different continents. Tissue sampling techniques were categorized based on (1) biopsy approach as either intrauterine and extrauterine and (2) techniques that were validated or not validated with a confirmatory hysterectomy pathology. Overall, there was significant heterogeneity in the tissue sampling techniques including intrauterine sampling obtained through hysteroscopic biopsy or resection and extrauterine tissue sampling obtained with needle biopsy by a percutaneous, transvaginal, laparoscopic, or ex-vivo approach. Sensitivity of these techniques varied significantly based on technique, tissue sampling location and the number of biopsies obtained, and was as low as 22.2% for an ultrasound-guided transvaginal biopsy of suspicious uterine lesions (4 biopsies per patient) and was as high as 97.8% for a laparoscopic guided myometrial biopsy of suspicious uterine lesions (10 biopsies per patient). Specificity for the identified tissue sampling techniques was more homogeneous ranging from 78.5% to 100% for all methods identified. The positive predictive value and negative predictive value ranges were 75.9% to 100% and 46.4% to 80% respectively among all tissue sampling techniques identified with confirmatory hysterectomy pathology. CONCLUSION: Because of the heterogeneity of the tissue sampling techniques, diverse patient populations, and significant conflicting recommendations, no conclusive recommendation on the optimal tissue sampling technique can be made. However, it would be reasonable to limit uterine tissue sampling for confirmatory diagnosis of adenomyosis in patients with a suspicion of adenomyosis based on both symptom profile and pelvic ultrasound, where a planned diagnostic laparoscopy for either infertility or pelvic pain has already been contemplated and scheduled, and where the confirmatory results may be of clinical benefit in discussing the prognosis of recurrent postoperative symptoms and guide any future treatment recommendations.
引用
- Movilla P, Morris S, Isaacson K, et al. A Systematic Review of Tissue Sampling Techniques for the Diagnosis of Adenomyosis. J Minim Invasive Gynecol. 2019. PMID: 31499191. doi:10.1016/j.jmig.2019.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。